1887

Abstract

The yellow fever virus attenuated 17D vaccine strain is a safe and effective vaccine and a valuable model system for evaluating immune responses against attenuated viral variants. This study compared the interactions of the commercially available yellow fever vaccine (YF-VAX), and the live-attenuated dengue vaccine PDK50 with dendritic cells (DCs), the main antigen-presenting cells at the initiation of immune responses. Similar to PDK50, infection with YF-VAX generated activated DCs; however, for YF-VAX, activation occurred with limited intracellular virus replication. The majority of internalized virus co-localized with endolysosomal markers within 90 min, suggesting that YF-VAX is processed rapidly in DCs. These results indicate that restricted virus replication and lysosomal compartmentalization may be important contributing factors to the success of the YF-VAX vaccine.

Loading

Article metrics loading...

/content/journal/jgv/10.1099/vir.0.82272-0
2007-01-01
2024-03-29
Loading full text...

Full text loading...

/deliver/fulltext/jgv/88/1/148.html?itemId=/content/journal/jgv/10.1099/vir.0.82272-0&mimeType=html&fmt=ahah

References

  1. Alvarez C. P., Lasala F., Carrillo J., Muñiz O., Corbi A. L., Delgado R. 2002; C-type lectins DC-SIGN and L-SIGN mediate cellular entry by Ebola virus in cis and in trans . J Virol 76:6841–6844 [CrossRef]
    [Google Scholar]
  2. Barba-Spaeth G., Longman R. S., Albert M. L., Rice C. M. 2005; Live attenuated yellow fever 17D infects human DCs and allows for presentation of endogenous and recombinant T cell epitopes. J Exp Med 202:1179–1184 [CrossRef]
    [Google Scholar]
  3. Barros V. E. D., Thomazini J. A., Figueiredo L. T. M. 2004; Cytopathological changes induced by selected Brazilian flaviviruses in mouse macrophages. J Microsc 216:5–14 [CrossRef]
    [Google Scholar]
  4. Brandler S., Brown N., Ermak T. H., Mitchell F., Parsons M., Zhang Z., Lang J., Monath T. P., Guirakhoo F. 2005; Replication of chimeric yellow fever virus-dengue serotype 1-4 virus vaccine strains in dendritic and hepatic cells. Am J Trop Med Hyg 72:74–81
    [Google Scholar]
  5. Brandriss M. W., Schlesinger J. J., Walsh E. E. 1990; Immunogenicity of a purified fragment of 17D yellow fever envelope protein. J Infect Dis 161:1134–1139 [CrossRef]
    [Google Scholar]
  6. Catteau A., Kalinina O., Wagner M.-C., Deubel V., Courageot M.-P., Desprès P. 2003; Dengue virus M protein contains a proapoptotic sequence referred to as ApoptoM . J Gen Virol 84:2781–2793 [CrossRef]
    [Google Scholar]
  7. Chu P. W. G., Westaway E. G. 1985; Replication strategy of Kunjin virus: evidence for recycling role of replicative form RNA as template in semiconservative and asymmetric replication. Virology 140:68–79 [CrossRef]
    [Google Scholar]
  8. Co M. D. T., Terajima M., Cruz J., Ennis F. A., Rothman A. L. 2002; Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E. Virology 293:151–163 [CrossRef]
    [Google Scholar]
  9. Desprès P., Flamand M., Ceccaldi P.-E., Deubel V. 1996; Human isolates of dengue type 1 virus induce apoptosis in mouse neuroblastoma cells. J Virol 70:4090–4096
    [Google Scholar]
  10. Diaz M. O., Ziemin S., Le Beau M. M., Pitha P., Smith S. D., Chilcote R. R., Rowley J. D. 1988; Homozygous deletion of the α - and β 1-interferon genes in human leukemia and derived cell lines. Proc Natl Acad Sci U S A 85:5259–5263 [CrossRef]
    [Google Scholar]
  11. Fox J. P., Lennette E. H., Manso C., Souza J. R. 1942; Encephalitis in man following vaccination with 17 D yellow fever virus. Am J Hyg 36:117–142
    [Google Scholar]
  12. Gardner J. P., Durso R. J., Arrigale R. R., Donovan G. P., Maddon P. J., Dragic T., Olson W. C. 2003; L-SIGN (CD 209L) is a liver-specific capture receptor for hepatitis C virus. Proc Natl Acad Sci U S A 100:4498–4503 [CrossRef]
    [Google Scholar]
  13. Groot H., Riberiro R. B. 1962; Neutralizing and haemagglutination-inhibiting antibodies to yellow fever 17 years after vaccination with 17D vaccine. Bull World Health Organ 27:699–707
    [Google Scholar]
  14. Gruenberg J. 2001; The endocytic pathway: a mosaic of domains. Nat Rev Mol Cell Biol 2:721–730 [CrossRef]
    [Google Scholar]
  15. Gubler D. J. 2004; Cities spawn epidemic dengue viruses. Nat Med 10:129–130 [CrossRef]
    [Google Scholar]
  16. Hahn C. S., Hahn Y. S., Rice C. M., Lee E., Dalgarno L., Strauss E. G., Strauss J. H. 1987; Conserved elements in the 3′ untranslated region of flavivirus RNAs and potential cyclization sequences. J Mol Biol 198:33–41 [CrossRef]
    [Google Scholar]
  17. Halary F., Amara A., Lortat-Jacob H., Messerle M., Delaunay T., Houles C., Fieschi F., Arenzana-Seisdedos F., Moreau J. F., Dechanet-Merville J. 2002; Human cytomegalovirus binding to DC-SIGN is required for dendritic cell infection and target cell trans-infection. Immunity 17:653–664 [CrossRef]
    [Google Scholar]
  18. Kroeger A., Nathan M., Hombach J. & the World Health Organization TDR Reference Group on Dengue; 2004; Dengue. Nat Rev Microbiol 2:360–361
    [Google Scholar]
  19. Kuno G., Chang G.-J. J., Tsuchiya K. R., Karabatsos N., Cropp C. B. 1998; Phylogeny of the genus Flavivirus . J Virol 72:73–83
    [Google Scholar]
  20. Lakadamyali M., Rust M. J., Babcock H. P., Zhuang X. 2003; Visualizing infection of individual influenza viruses. Proc Natl Acad Sci U S A 100:9280–9285 [CrossRef]
    [Google Scholar]
  21. Lambeth C. R., White L. J., Johnston R. E., de Silva A. M. 2005; Flow cytometry-based assay for titrating dengue virus. J Clin Microbiol 43:3267–3272 [CrossRef]
    [Google Scholar]
  22. Lee E., Lobigs M. 2002; Mechanism of virulence attenuation of glycosaminoglycan-binding variants of Japanese encephalitis virus and Murray Valley encephalitis virus. J Virol 76:4901–4911 [CrossRef]
    [Google Scholar]
  23. Liprandi F., Walder R. 1983; Replication of virulent and attenuated strains of yellow fever virus in human monocytes and macrophage-like cells (U937). Arch Virol 76:51–61 [CrossRef]
    [Google Scholar]
  24. Marianneau P., Desprès P., Deubel V. 1999a; Recent knowledge on the pathogenesis of yellow fever and questions for the future. Bull Soc Pathol Exot 92:432–434 (in French
    [Google Scholar]
  25. Marianneau P., Steffan A.-M., Royer C., Drouet M.-T., Jaeck D., Kirn A., Deubel V. 1999b; Infection of primary cultures of human Kupffer cells by dengue virus: no viral progeny synthesis, but cytokine production is evident. J Virol 73:5201–5206
    [Google Scholar]
  26. Mathew A., Kurane I., Green S., Vaughn D. W., Kalayanarooj S., Suntayakorn S., Ennis F. A., Rothman A. L. 1999; Impaired T cell proliferation in acute dengue infection. J Immunol 162:5609–5615
    [Google Scholar]
  27. Navarro-Sanchez E., Altmeyer R., Amara A., Schwartz O., Fieschi F., Virelizier J.-L., Arenzana-Seisdedos F., Desprès P. 2003; Dendritic-cell-specific ICAM3-grabbing non-integrin is essential for the productive infection of human dendritic cells by mosquito-cell-derived dengue viruses. EMBO Rep 4:723–728 [CrossRef]
    [Google Scholar]
  28. Palmer D. R., Sun P., Celluzzi C., Bisbing J., Pang S., Sun W., Marovich M. A., Burgess T. 2005; Differential effects of dengue virus on infected and bystander dendritic cells. J Virol 79:2432–2439 [CrossRef]
    [Google Scholar]
  29. Poland J. D., Calisher C. H., Monath T. P., Downs W. G., Murphy K. 1981; Persistence of neutralizing antibody 30–35 years after immunization with 17D yellow fever vaccine. Bull World Health Organ 59:895–900
    [Google Scholar]
  30. Putnak J. R., Schlesinger J. J. 1990; Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1. NS2a and NS2b. J Gen Virol 71:1697–1702 [CrossRef]
    [Google Scholar]
  31. Quaresma J. A. S., Barros V. L. R. S., Fernandes E. R., Pagliari C., Takakura C., da Costa Vasconcelos P. F., de Andrade H. F. Jr, Duarte M. I. S. 2005; Reconsideration of histopathology and ultrastructural aspects of the human liver in yellow fever. Acta Trop 94:116–127 [CrossRef]
    [Google Scholar]
  32. Querec T., Bennouna S., Alkan S., Laouar Y., Gorden K., Flavell R., Akira S., Ahmed R., Pulendran B. 2006; Yellow fever vaccine YF-17D activates multiple dendritic cell subsets via TLR2, 7, 8, and 9 to stimulate polyvalent immunity. J Exp Med 203:413–424 [CrossRef]
    [Google Scholar]
  33. Rao M., Rothwell S. W., Wassef N. M., Pagano R. E., Alving C. R. 1997; Visualization of peptides derived from liposome-encapsulated proteins in the trans -Golgi area of macrophages. Immunol Lett 59:99–105 [CrossRef]
    [Google Scholar]
  34. Reinhardt B., Jaspert R., Niedrig M., Kostner C., L'age-Stehr J. 1998; Development of viremia and humoral and cellular parameters of immune activation after vaccination with yellow fever virus strain 17D: a model of human flavivirus infection. J Med Virol 56:159–167 [CrossRef]
    [Google Scholar]
  35. Schlesinger J. J., Brandriss M. W., Cropp C. B., Monath T. P. 1986; Protection against yellow fever in monkeys by immunization with yellow fever virus nonstructural protein NS1. J Virol 60:1153–1155
    [Google Scholar]
  36. Tassaneetrithep B., Burgess T. H., Granelli-Piperno A., Trumpfheller C., Finke J., Sun W., Eller M. A., Pattanapanyasat K., Sarasombath S. other authors 2003; DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197:823–829 [CrossRef]
    [Google Scholar]
  37. Theiler M., Smith H. H. 1937; The use of yellow fever virus by in vitro cultivation for human immunization. J Exp Med 65:787–800 [CrossRef]
    [Google Scholar]
  38. Uchil P. D., Satchidanandam V. 2003; Characterization of RNA synthesis, replication mechanism, and in vitro RNA-dependent RNA polymerase activity of Japanese encephalitis virus. Virology 307:358–371 [CrossRef]
    [Google Scholar]
  39. van Kooyk Y., Geijtenbeek T. B. 2003; DC-SIGN: escape mechanism for pathogens. Nat Rev Immunol 3:697–709 [CrossRef]
    [Google Scholar]
http://instance.metastore.ingenta.com/content/journal/jgv/10.1099/vir.0.82272-0
Loading
/content/journal/jgv/10.1099/vir.0.82272-0
Loading

Data & Media loading...

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error